Daiichi Sankyo
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Daiichi Sankyo sits in the top decile of US sponsors by registered trial count (#139 of 15,742 sponsors by registered trial count).
Daiichi Sankyo: 236 sponsored US clinical trials, 29 recruiting.
Daiichi Sankyo sponsors 236 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 167 completed. 71 of these trials are in Phase 3-4 (later-stage) and 153 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 7 trials.
Top-decile sponsor footprint
Daiichi Sankyo ranks in the top decile of sponsors by registered trial count (#139 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
167 of 189 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
236 total, page 5 of 5
Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
NCT00107900
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
NCT00143520
Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes
NCT00151762
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
NCT00272909
WelChol® With Metformin in Treating Patients With Type 2 Diabetes
NCT00147719
WelChol® and Insulin in Treating Patients With Type 2 Diabetes
NCT00151749
WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes
NCT00147758
An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension
NCT00185068
A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin
NCT00185094
DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma
NCT00080834
DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00077077
Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.
NCT00151788
Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure
NCT00259038
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
NCT00064220
Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT00061854
Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol
NCT00754039
Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor
NCT00055952
Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma
NCT00055939
Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease
NCT00185042
A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.
NCT00753779
Vascular Improvement With Olmesartan Medoxomil Study
NCT00772499
A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.
NCT00755352
A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.
NCT00754507
Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00023972
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
NCT00017511
DX-8951f in Treating Patients With Metastatic Stomach Cancer
NCT00017212
DX-8951f in Treating Patients With Biliary Cancer
NCT00005938
DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix
NCT00004866
DX-8951f in Treating Patients With Liver Cancer
NCT00004108
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
NCT00004212
Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00004060
Chemotherapy in Treating Women With Metastatic Breast Cancer
NCT00004046
Chemotherapy in Treating Patients With Prostate Cancer
NCT00004045
DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas
NCT00003951
Chemotherapy in Treating Patients Who Have Hematologic Cancer
NCT00004047
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
NCT00320827
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 90 |
| Phase 2 | 63 |
| Phase 3 | 50 |
| Phase 4 | 21 |
What is open in the Daiichi Sankyo pipeline
29 recruiting of 236 indexed (12% open); 167 completed (71%).
Phase mix: 71 late (III/IV) vs 153 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumor (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Daiichi Sankyo: open-pipeline peers nationwide
Peers matched on 236 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Daiichi Sankyo sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 236 trials (± recruiting share)
- Loma Linda University · 237 trials · 15% recruiting
- Henry Ford Health System · 234 trials · 18% recruiting
- Incyte Corporation · 239 trials · 15% recruiting
- University of Massachusetts, Worcester · 240 trials · 13% recruiting
Sponsors near 12% open enrollment (± trial volume)
- University of Iowa · 12% recruiting · 228 trials
- Augusta University · 12% recruiting · 106 trials
- National Institute of Mental Health (NIMH) · 12% recruiting · 343 trials
- National Heart, Lung, and Blood Institute (NHLBI) · 12% recruiting · 501 trials
Related
What to do with this Daiichi Sankyo page
236 registered trials is a research-attention snapshot, not an endorsement of Daiichi Sankyo or any single study.
- 29 of Daiichi Sankyo's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumor is the condition Daiichi Sankyo studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Daiichi Sankyo pipeline card: 236 registered trials from official public datasets.Report a data error.